FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2562-2575 December 20, 2007 Number 25 Next

Henrik Ekberg, M.D., Ph.D., Helio Tedesco-Silva, M.D., Alper Demirbas, M.D., tefan Vítko, M.D., Björn Nashan, M.D., Ph.D., Alp Gürkan, M.D., F.A.C.S., Raimund Margreiter, M.D., Christian Hugo, M.D., Josep M. Grinyó, M.D., Ulrich Frei, M.D., Yves Vanrenterghem, M.D., Ph.D., Pierre Daloze, M.D., Philip F. Halloran, M.D., Ph.D., for the ELITE–Symphony Study

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Leichtman, A. B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens.

Methods We randomly assigned 1645 renal-transplant recipients to receive standard-dose cyclosporine, mycophenolate mofetil, and corticosteroids, or daclizumab induction, mycophenolate mofetil, and corticosteroids in combination with low-dose cyclosporine, low-dose tacrolimus, or low-dose sirolimus. The primary end point was the estimated glomerular filtration rate (GFR), as calculated by the Cockcroft–Gault formula, 12 months after transplantation. Secondary end points included acute rejection and allograft survival.

Results The mean calculated GFR was higher in patients receiving low-dose tacrolimus (65.4 ml per minute) than in the other three groups (range, 56.7 to 59.4 ml per minute). The rate of biopsy-proven acute rejection was lower in patients receiving low-dose tacrolimus (12.3%) than in those receiving standard-dose cyclosporine (25.8%), low-dose cyclosporine (24.0%), or low-dose sirolimus (37.2%). Allograft survival differed significantly among the four groups (P=0.02) and was highest in the low-dose tacrolimus group (94.2%), followed by the low-dose cyclosporine group (93.1%), the standard-dose cyclosporine group (89.3%), and the low-dose sirolimus group (89.3%). Serious adverse events were more common in the low-dose sirolimus group than in the other groups (53.2% vs. a range of 43.4 to 44.3%), although a similar proportion of patients in each group had at least one adverse event during treatment (86.3 to 90.5%).

Conclusions A regimen of daclizumab, mycophenolate mofetil, and corticosteroids in combination with low-dose tacrolimus may be advantageous for renal function, allograft survival, and acute rejection rates, as compared with regimens containing daclizumab induction plus either low-dose cyclosporine or low-dose sirolimus or with standard-dose cyclosporine without induction. (ClinicalTrials.gov number, NCT00231764 [ClinicalTrials.gov] .)

Source Information

From Lund University, Malmö, Sweden (H.E.); Federal University, São Paulo (H.T.-S.); Akdeniz University, Antalya, Turkey (A.D.); Institutu Klinické a Experimentální Medicíny, Prague, Czech Republic (S.V.); Medizinische Hochschule, Hannover, Germany (B.N.); S.B. Tepecik Hospital, Izmir, Turkey (A.G.); Universitaetsklinik, Innsbruck, Austria (R.M.); University Hospital, Erlangen, Germany (C.H.); Ciutat Universitaria de Bellvitge, Barcelona (J.M.G.); Charité, Virchow-Klinikum, Berlin (U.F.); Katholieke Universiteit Leuven, Leuven, Belgium (Y.V.); Notre-Dame Hospital, Centre Hospitalier de l'Université de Montréal, Montreal (P.D.); and University of Alberta, Edmonton, Canada (P.F.H.).

Address reprint requests to Dr. Ekberg at the Department of Nephrology and Transplantation, University Hospital, 205 03 Malmö, Sweden, or at henrik.ekberg{at}med.lu.se.

Full Text of this Article

Related Letters:

Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Guba M., Jauch K.-W., Krüger B., Banas M., Hoffmann U., Krämer B. K., Jung B., Banas B., van den Hoogen M., Hilbrands L., Ekberg H., Halloran P. F.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:2518-2520, Jun 5, 2008. Correspondence

This article has been cited by other articles:

• Kufner, S., Hausleiter, J., Ndrepepa, G., Schulz, S., Bruskina, O., Byrne, R. A., Fusaro, M., Kastrati, A., Schomig, A., Mehilli, J., for the OSIRIS Trial Investigators, (2009). Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. J Am Coll Cardiol Intv 2: 1142-1148 [Abstract] [Full Text]  
• Naesens, M., Lerut, E., de Jonge, H., Van Damme, B., Vanrenterghem, Y., Kuypers, D. R. J. (2009). Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts. J. Am. Soc. Nephrol. 20: 2468-2480 [Abstract] [Full Text]  
• Treleaven, D. J, Clase, C. M (2009). Use of erythropoietins in patients with renal transplants. BMJ 339: b3825-b3825 [Full Text]  
• Meier-Kriesche, H.-U., Schold, J. D., Vanrenterghem, Y., Halloran, P. F., Ekberg, H. (2009). Uric Acid Levels Have No Significant Effect on Renal Function in Adult Renal Transplant Recipients: Evidence from the Symphony Study. CJASN 4: 1655-1660 [Abstract] [Full Text]  
• Fangmann, J., Arns, W., Marti, H.-P., Hauss, J., Ketteler, M., Beckurts, T., Boesmueller, C., Pohanka, E., Martin, P.-Y., Gerhardt, M., Farese, S., Neumayer, H.-H., Floege, J., Gurr, C., Budde, K., on behalf of the DACH Study Group, (2009). Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrol Dial Transplant 0: gfp468v1-gfp468 [Abstract] [Full Text]  
• Grinyo, J. M., Ekberg, H., Mamelok, R. D., Oppenheimer, F., Sanchez-Plumed, J., Gentil, M. A., Hernandez, D., Kuypers, D. R., Brunet, M. (2009). The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 24: 2269-2276 [Abstract] [Full Text]  
• Noel, C., Abramowicz, D., Durand, D., Mourad, G., Lang, P., Kessler, M., Charpentier, B., Touchard, G., Berthoux, F., Merville, P., Ouali, N., Squifflet, J.-P., Bayle, F., Wissing, K. M., Hazzan, M. (2009). Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. J. Am. Soc. Nephrol. 20: 1385-1392 [Full Text]  
• Domhan, S., Zeier, M., Abdollahi, A. (2009). Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant 24: 1097-1103 [Full Text]  
• Birnbaum, L. M., Lipman, M., Paraskevas, S., Chaudhury, P., Tchervenkov, J., Baran, D., Herrera-Gayol, A., Cantarovich, M. (2009). Management of Chronic Allograft Nephropathy: A Systematic Review. CJASN 4: 860-865 [Abstract] [Full Text]  
• Naesens, M., Kuypers, D. R. J., Sarwal, M. (2009). Calcineurin Inhibitor Nephrotoxicity. CJASN 4: 481-508 [Abstract] [Full Text]  
• Weichhart, T, Saemann, M D (2008). The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 67: iii70-iii74 [Abstract] [Full Text]  
• Ebah, L. M., Mapstone, N., Gibson, S. P., Woywodt, A. (2008). Diagnosis by inclusion. NDT Plus 1: 349-353 [Full Text]  
• Guba, M., Jauch, K.-W., Kruger, B., Banas, M., Hoffmann, U., Kramer, B. K., Jung, B., Banas, B., van den Hoogen, M., Hilbrands, L., Ekberg, H., Halloran, P. F. (2008). Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. NEJM 358: 2518-2520 [Full Text]  
• Srinivas, T. R., Meier-Kriesche, H.-U. (2008). Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects: Objectives and Interim Result. CJASN 3: S101-S116 [Abstract] [Full Text]  
• Leichtman, A. B. (2007). Balancing Efficacy and Toxicity in Kidney-Transplant Immunosuppression. NEJM 357: 2625-2627 [Full Text]